DCTH
Delcath Systems
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 2
Sell signal 1
consensus rating "Strong Buy"
Revenue Beats Expectation
EPS Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About DCTH
Delcath Systems, Inc.
A company that offers a system to administers chemotherapy and other therapeutic agents for tumors
Healthcare Equipment and Supplies
Invalid Date
05/01/2020
NASDAQ Stock Exchange
96
12-31
Common stock
566 Queensbury Avenue, Queensbury, NY 12804
--
Delcath Systems, Inc., was incorporated in Delaware in August 1988. The company is an interventional oncology company focused on the treatment of primary and liver metastatic cancers. The Company's lead product, HEPZATOTM KIT (" HEPZATO "melphalan for Injection/liver Delivery System), is a drug/device combination product approved by the U.S. Food and Drug Administration (FDA) on August 14, 2023 for the treatment of adult patients with uveal melanoma with unresectable liver metastases, Liver metastases in this patient affect less than 50% of the liver, and there is no extrahepatic disease, or extrahepatic disease is limited to bones, lymph nodes, and subcutaneous tissue.
Company Financials
EPS
DCTH has released its 2024 Q4 earnings. EPS was reported at -0.11, versus the expected 0.01, missing expectations. The chart below visualizes how DCTH has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
DCTH has released its 2024 Q4 earnings report, with revenue of 15.10M, reflecting a YoY change of 2701.48%, and net profit of -3.40M, showing a YoY change of 69.49%. The Sankey diagram below clearly presents DCTH’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
